TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Exchange sourced- Local ticker
- TEVA
- ISIN
- IL0006290147
- Exchange
- Tel Aviv Stock Exchange, XTAE
- Primary market
- Israel
Figures as of 6 November 2026, 18:00 UTC. Refreshed weekly.
What we hold
Counted over 10 years, by bundle.
Counts are classified documents, not pages. A name with no filings in a bundle still shows the bundle, so an empty row is a fact about the company rather than a gap in coverage.
| Bundle | Documents held | Most recent |
|---|---|---|
| Core Financials & GovernanceAnnual and interim reports, financial statements, AGM and remuneration material | 956 | 5 Nov 2026Proposed Sale of Securities - Rule 144 Filing, NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 |
| Corporate EventsAnnouncements, results releases, corporate actions, director dealings | 344 | 3 Nov 2026Current Report, Unscheduled Material Events |
| Earnings IntelligenceEarnings call transcripts, results presentations, capital markets days | 121 | 3 Nov 2026Q3 2026 |
| Sustainability & PoliciesSustainability reports, transition plans, supplier and human rights policies | 32 | 19 Jun 20242023 US Sustainability Highlights Report |
| MiscellaneousEverything the taxonomy places outside the four bundles above | 96 | 14 Sep 2026Delisting, Notice of stock delisting from an exchange |
| All bundles | 1,516 |
Most recent documents
The ten most recent, newest first. Every document carries the date it was published, the classification we assigned, and its length.
The full record for TEVA PHARMACEUTICAL INDUSTRIES LIMITED, every document in it and the whole archive behind it, is in Orbit Insight. Opening a document costs one credit and trial accounts start with 500.
| Document | Bundle | Published | Pages | Open |
|---|---|---|---|---|
| Proposed Sale of Securities - Rule 144 Filing, NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933Managers’ Transactions | Financials | 5 Nov 2026 | 3 | Open in Insight |
| Quarterly ReportQuarterly Reports | Financials | 3 Nov 2026 | 75 | Open in Insight |
| Current Report, Unscheduled Material EventsCurrent Report Filings | Events | 3 Nov 2026 | 3 | Open in Insight |
| Q3 2026Earnings Call Transcript - ECM | Earnings | 3 Nov 2026 | 17 | Open in Insight |
| Q3 2026- PresenationConference Call Presentation | Earnings | 3 Nov 2026 | 70 | Open in Insight |
| SCHEDULE 13G/AMajority Shareholder/Substantial Holding | Financials | 2 Nov 2026 | 4 | Open in Insight |
| Security Ownership Statement, Initial statement of beneficial ownership of securitiesStatement of Beneficial Ownership of Securities | Financials | 8 Oct 2026 | 2 | Open in Insight |
| Security Sale/Purchase Record, Statement of changes in beneficial ownership of securitiesStatement of Beneficial Ownership of Securities | Financials | 22 Sep 2026 | 2 | Open in Insight |
| Delisting, Notice of stock delisting from an exchangeMiscellaneous | Other | 14 Sep 2026 | 1 | Not yet openable |
| 8-A12B/AMiscellaneous | Other | 14 Sep 2026 | 10 | Not yet openable |
How it reaches you. And how fast.
The same facts are attached to every name in the universe, which is what makes a coverage answer checkable rather than a claim.
Open the full Israel coverage detail for the exchanges behind that company count, what the year’s volume is made of, and how the median latency is distributed.
Follow TEVA PHARMACEUTICAL INDUSTRIES LIMITED and the rest of your universe.
Paste every name you hold into Orbit Insight and get this view for all of them, plus the documents themselves. Trial accounts start with 500 credits.
Missing a filing for IL0006290147?
If a document you expect for this name is not held, tell us which one and we will assess a backfill.